Ultrasound contrast agent Optison from Molecular Biosystems has been approved in Europe, according to San Diego-based MBI and its marketing partner, Mallinckrodt of St. Louis. Mallinckrodt now has rights to sell the agent in the 15 countries of the
Ultrasound contrast agent Optison from Molecular Biosystems has been approved in Europe, according to San Diego-based MBI and its marketing partner, Mallinckrodt of St. Louis. Mallinckrodt now has rights to sell the agent in the 15 countries of the European Union, with sales to begin first in Germany, Austria, and the U.K.
MBI this month also announced financial results for the fourth quarter (end-March) that showed the impact of Optison sales in the U.S., which began in January (SCAN 1/14/98). MBIs Optison sales to Mallinckrodt totaled $700,000, exceeding the companys expectations. MBIs total revenues for the period were $2 million, compared with sales of $1.5 million in the fourth quarter of 1996. MBI had a net loss of $5.9 million in the most recent period, compared with a net loss of $4.3 million in the fourth quarter of 1996.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.